The Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Angelini has fallen short of its standards by ...

Novo Nordisk has just released the topline findings from two eagerly anticipated phase 3 trials of its oral formulation of ...

Whilst the NHS indubitably runs on international talent, however, this does not stop our system from pushing overseas nurses ...

The positive result in OCEANIC-STROKE means that asundexian can potentially now sit alongside prostate cancer therapy Nubeqa (darolutamide) and kidney disease treatment Kerendia (finerenone) as a near ...

J&J is also running mid-stage trials of a tau active immunotherapy codenamed JNJ-2056 for Alzheimer', while other active tau ...

Eli Lilly has become the first pharma group to reach a value of more than $1 trillion, joining a select group of companies ...

Merck KGaA has teamed up with Flagship Pioneering's Valo Health on an ambitious project to apply AI to the discovery of novel drug targets and therapeutics for Parkinson's disease. The partnership ...

On World Diabetes Day, Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug designed to delay the progression of type 1 diabetes (T1D). The EMA's human ...

Venatorx Pharma has moved a step closer to what has unfortunately become a rare event in pharma – the filing of a new antibiotic designed to tackle the increasing pressing problem of antimicrobial ...

Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Both these factors can be tied in part to J&J’s strong presence in the consumer sector – but behind household name products is a strong pharmaceutical backbone that has emerged over the company’s long ...

A report has suggested the UK is seeing an exodus of skilled science, technology, engineering, and mathematics (STEM) workers to other countries, placing the country's economic future at risk. The ...